PHR:NYE-Phreesia Inc (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 26.98

Change

+0.43 (+1.62)%

Market Cap

N/A

Volume

0.46M

Analyst Target

USD 30.11
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-07 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
SOLV Solventum Corp.

-0.45 (-0.65%)

USD 10.78B
DOCS Doximity Inc

-0.48 (-0.87%)

USD 9.97B
WEAV Weave Communications Inc

-0.12 (-0.75%)

USD 1.13B
MPLN MultiPlan Corporation

+0.27 (+2.23%)

USD 0.23B
AMWL American Well Corp

-0.11 (-1.49%)

USD 0.11B
OWLT Owlet Inc

-0.03 (-0.67%)

USD 0.08B
TDOC Teladoc Inc

-0.21 (-2.10%)

N/A
FOXO FOXO Technologies Inc.

-0.02 (-5.92%)

N/A
EVH Evolent Health Inc

+0.64 (+5.35%)

N/A
VEEV Veeva Systems Inc Class A

+5.57 (+2.63%)

N/A

ETFs Containing PHR

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.23% 90% A- 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.23% 90% A- 95% A
Trailing 12 Months  
Capital Gain 17.46% 80% B- 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.46% 80% B- 69% C-
Trailing 5 Years  
Capital Gain 0.75% 50% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.75% 50% F 28% F
Average Annual (5 Year Horizon)  
Capital Gain 10.96% 70% C- 67% D+
Dividend Return 10.96% 70% C- 61% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 66.63% 60% D- 14% F
Risk Adjusted Return 16.46% 80% B- 32% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector